

# Association between placenta previa and risk of hypertensive disorders of pregnancy: a meta-analysis based on 7 cohort studies

X.-A. YIN<sup>1,2</sup>, Y.-S. LIU<sup>1</sup>

<sup>1</sup>Center of Reproductive Medicine, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China

<sup>2</sup>Department of Obstetrics and Gynecology, Affiliated Chaohu Hospital of Anhui Medical University, Hefei, Anhui, China

**Abstract. – OBJECTIVE:** The aim of this research is to evaluate the association between placenta previa and hypertensive disorders of pregnancy (HDP).

**MATERIALS AND METHODS:** A computerized literature search was carried out on PubMed to collect relevant articles on the association between placenta previa and HDP before November 2013. Pooled relative risk (RR) and 95% confidence intervals (CIs) were used to assess the strength of the associations.

**RESULTS:** A total of 7 cohort studies were identified according to the inclusion criteria. Overall, a significantly inverse correlation between placenta previa and HDP was found when all study results were pooled into the meta-analysis (RR = 0.55, 95% CI: 0.32-0.97). For subgroup analyses, the same results were found in pregnancy-induced hypertension (PIH) group (RR = 0.36, 95% CI: 0.23-0.57) but not in other HDPs group (RR = 0.94, 95% CI: 0.44-2.00).

**CONCLUSIONS:** This meta-analysis suggested a reduced risk for PIH in women with placenta previa.

*Key Words:*

Hypertensive disorders, Pregnancy-induced hypertension, Preeclampsia, Placenta previa, Pregnancy, Meta-analysis.

## Introduction

Hypertensive disorders of pregnancy (HDP) are the main causes of maternal and perinatal morbidity and mortality<sup>1</sup>. HDP is comprised of chronic hypertension, gestational hypertension, preeclampsia and eclampsia, while gestational hypertension and preeclampsia were also referred as pregnancy-induced hypertension (PIH)<sup>2</sup>. The mechanisms of HDP have not yet been fully elucidated. However, growing evidence supports that the placenta plays a critical role in the pathogenesis of preeclampsia<sup>3</sup>

<sup>5</sup>. It is now commonly accepted that reduced uteroplacental perfusion and placental ischemia/hypoxia, which develops as a result of abnormal cytotrophoblast invasion of spiral arterioles, trigger a cascade of events leading to the maternal disorder<sup>6-9</sup>. In the placenta previa (PP), the blood supply and oxygenation of a placenta implanted in the lower uterine segment are thought to be increased compared with those in a placenta implanted in the upper uterine segment<sup>10</sup>. As the increased blood supply may improve the situation of placental ischemia, we speculated that the risk of hypertensive disorders is lower in placenta previa compared with normally implanted placenta.

Early in 1958, Bieniarz<sup>11</sup> reported an inverse association between lower placental implantation in the uterus and hypertension in later pregnancy. After twenty years, Nicolaides et al<sup>12</sup> showed that low implantation of the placenta might protect against the development of pregnancy-induced hypertension and was associated with improved values in tests of placental function. Subsequently, several retrospective studies based on a large cohort of population have further confirmed this hypothesis by the controlling the confounding factors such as parity, preterm or term delivery, cigarette smoking, maternal age, race, maternal height and weight at delivery<sup>10,13,14</sup>. However, some other studies did not show the same consequence. Two retrospective cohort studies<sup>15,16</sup> reported the 1.5 odds ratio (OR) (95% confidence interval (CI) = 0.9-2.5) and 0.88 OR (95% CI = 0.64-1.20) respectively, which did not show the inverse relation.

Recently, two case-control studies<sup>17,18</sup> have demonstrated a strong inverse relation between placenta previa and preeclampsia. To obtain an overall quantitative estimation of the association between placenta previa and HDP, a meta-analysis was performed.

## Materials and Methods

### Searching Method

The basis diagnosis of the placenta previa included complete, partial and marginal praevia and low-lying placenta<sup>19</sup>. According to these criteria, we searched related literatures in PubMed database before November 2013 using the following key words: “hypertension,” “preeclampsia,” or “eclampsia” combined with “placenta previa”. Furthermore, we screened the reference lists from all relevant articles to identify additional studies. There were no restrictions regarding language or country.

### Inclusion/Exclusion Criteria

Eligible studies had to meet all of the following criteria: (1) cohort study on the association between placenta previa and HDP; (3) with relative risk estimates and respective variance, or the relevant information needed to calculate them. Studies were excluded when they were: (1) not a cohort study; (2) duplicate of previous publication; (3) based on incomplete data; (4) meta-analyses, letters, reviews, or editorial articles.

### Data Extraction

For all included studies, we extracted the following information: the name of the first author, year of publication, the country in which the study was conducted, study design, study period, number of subjects, risk estimates with corresponding 95% (CIs) and adjustment.

### Statistical Analysis

Pooled relative risks (RRs) and 95% CIs were used to assess the strength of the associations. For simplicity, we took the OR for cohort studies as the estimate of RR. Heterogeneity among studies was examined using Q-test and  $I^2$  score<sup>20</sup>. Dependent on the results of heterogeneity test among individual studies, the fixed effect model (Mantel-Haenszel) or random effect model (DerSimonian and Laird) was selected to summarize the pooled RR<sup>21</sup>. The significance of the pooled RR was determined by the z test. Publication bias was assessed using the funnel plot and Egger’s test<sup>22,23</sup>.  $p$  value less than 0.05 was considered statistically significant. All statistical analyses were conducted using Stata 12.0 software (Stata-Corp, College Station, TX, USA).

## Results

### Study Selection

The process of study selection was shown in Figure 1. Ten potentially relevant studies were retrieved for further evaluation<sup>9,11-17,24,25</sup>. Three studies were excluded as they were case-control studies and one of them was a duplication<sup>17,18,25</sup>. Thus, a total of 7 studies were included in this meta-analysis. Table I listed the main characteristics of each study included in this meta-analysis. Among the 7 cohort studies, four studies offered adjusted RRs, one study offered crude RR, and two studies did not offer RR.

### Quantitative Synthesis

The RRs of hypertension disorders in patients with placenta previa in all seven studies were shown in Figure 2. A reduced risk for HDP was observed in the women with placenta previa (RR = 0.55, 95% CI: 0.32-0.97). There was statistically significant heterogeneity across the studies ( $p < 0.001$ ,  $I^2 = 86.1\%$ ). In 7 included studies, 3 studies were defined as gestational hypertension (BP  $\geq 140/90$  mmHg) with or without proteinuria, 1 study was preeclampsia, and 3 studies were general HDP that included gestational hyperten-





Figure 1. Literature screening and exclusion.

Table 1. Comparison of measured variables before and after intervention in BAL fluid.

Reference	Country	Study design	Study period	Definition of hypertension	Total number of subjects	Adjustment	Hypertensive disorder		No Hypertensive disorder	
							Placenta previa	No placenta previa	Placenta previa	No placenta previa
Nicolaides et al. 1982 <sup>10</sup>	British	Cohort	1973-1981	PIH	24750	N	6	3744	195	20805
Leiberman et al. 1991 <sup>8</sup>	Israel	RCC	1972-1986	HDP	106866	Parity, preterm or term delivery	12	5867	479	100508
Jelsema et al. 1991 <sup>23</sup>	USA	Cohort	N	PE	6576	Maternal weight, parity, gestational age	4	536	117	5919
Ananth et al. 1997 <sup>11</sup>	Canada	RCC	1980-1993	PIH	121082	Parity, Cigarette smoking	24	14142	392	106549
Wang et al. 1999 <sup>12</sup>	Malaysia	RCC	1989-1998	PIH	258444	Maternal age, race (Chines, Malay, Indians), diabetes mellitus, maternal height and weight at delivery and maturity	3	1902	123	23816
Huang et al. 2007 <sup>13</sup>	Taipei	RCC	1990-2003	HDP	37702	Maternal age, parity, previous induced abortion, previous cesarean deliveries, prepregnancy body mass index, years of education, previous fetal death, previous preterm birth, previous placenta previa, marital status, amniocentesis, conception methods, presence of uterine fibroids, uterine malformation, employment during pregnancy, smoking during pregnancy, and fetal sex	16	640	441	36605
Rosenberg et al. 2011 <sup>14</sup>	Israel	RCC	1988-2009	HDP	185476	N	41	11082	730	173623

HDP: hypertensive disorder of pregnancy, PIH: pregnancy-induced hypertension, PE: preeclampsia, N: not offered, RCC: Retrospective cohort study.



**Figure 2.** The forest plot of all selected studies on the association between placenta previa and HDP

sion, preeclampsia/eclampsia/superimposed hypertension, and chronic hypertension. We categorized 4 studies (the former two) as PIH subgroup and defined another 3 studies as other HDP subgroup, and the subgroup analyses for PIH and other HDP were conducted. The RR in other HDP group was 0.94 (95% CI, 0.44-2.00), and that in PIH group was 0.36 (95% CI, 0.23-0.57) (Figure 2). A strong inverse relation between placenta previa and PIH was observed. When we pooled the adjusted RRs into analyses (Figure 3), the risk estimate was 0.68 (95% CI: 0.35-1.00), which also showed an inverse relation between placenta previa and HDP.

#### **Sensitive Analysis and Bias Diagnosis**

To compare the difference and evaluate the sensitivity of this meta-analysis, we used both models (the fixed effect model and random effect model) to evaluate the stability of the meta-analysis. All results were not materially altered (data not shown). Hence, results of the sensitivity analysis suggest that the data in this meta-analysis are credible.

The Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The shape of the funnel plots did not reveal obvious asymmetry (data not shown). Then, the Egger's test was used to provide the statistical evidence of funnel plot symmetry. There was no evidence of publication bias in overall analysis ( $p$  for Egger's test = 0.329).

#### **Discussion**


Some studies have focused on the association between placenta previa and the risk of hypertensive disorders. However, the results were not consistent. Cobo et al<sup>26</sup> reported a severe preeclampsia case that occurred in a patient with placenta previa. Jelsema et al<sup>24</sup> reported the association between decreased occurrence of preeclampsia and placenta previa and a strong association between placenta previa and premature delivery. Therefore, we conducted this meta-analysis to demonstrate the association between placenta previa and the risk of hypertensive disorders based on 7 indi-

vidual cohort studies. In the study, we found a protective relation between placenta previa and hypertensive disorders (RR = 0.55, 95% CI: 0.32-0.97), even after controlling confounding factors such as parity, preterm or term delivery. In subgroup analysis, we observed a strong inverse correlation between placenta previa and PIH (RR = 0.36, 95% CI: 0.23-0.57).

PIH is associated with an increase in the prevalence of cardiovascular disease risk in later life of Japanese women<sup>27</sup>. A recent study<sup>28</sup> reported that almost half of early-onset preeclampsia women will develop hypertension, as opposed to 39% and 25% of women in the PIH and late-onset preeclampsia groups, respectively. The factors including extremes of maternal age, nulliparity, prior history of pregnancy-induced hypertension, and high body mass index are found to be associated with PIH<sup>29</sup>, while cigarette smoking during pregnancy is a protective factor for PIH<sup>30</sup>. In the present meta-analysis, we observed a reduced risk of HDP especially PIH in the women with placenta previa, suggesting that placenta previa is another protective factor for HDP. Considering the previous studies<sup>31</sup>, several possible interpretations may be used to explain this finding. First of all, the placenta implanted in the lower uterine may contribute to the venous drainage and reduce the risk of toxemia. Secondly, the improved blood supply and oxygenation

of the placenta implanted in the lower uterine segment may have a role in the prevention of PIH<sup>10,13</sup>. In addition, abnormal or incomplete invasion of endometrial arterioles by trophoblastic cells in the early development of the placenta may result in later placental ischemia and induce endothelial damage and PIH<sup>32</sup>. Although some researchers<sup>33,34</sup> have found no association or a positive association between placenta previa and the frequency of PIH, this meta-analysis validated the inverse correlation between placenta previa and HDP (particularly PIH) in 7 large cohorts of population. We speculate that the discrepancy among previous studies may be caused by many factors, such as different population properties, size of subjects, etc. However, we are confident that the finding from this meta-analysis is more convincing than any single study.

However, this meta-analysis may have a couple of limitations. Firstly, the time span of this meta-analysis is very long and the diagnosis criteria for HDP used in every study may be different. Secondly, the confounding factors were not corrected in 4 studies while the given confounding factors in other 3 studies were inconsistent. Nevertheless, the inverse relation between placenta previa and HDP was also observed when the adjusted RRs were used, which may reduce the influence of above limitations.



**Figure 3.** The forest plot of all studies with adjusted RRs on the association between placenta previa and HDP.

## Conclusions

This meta-analysis provides quantitative evidence for the inverse correlation between placenta previa and HDP/PIH. However, the precise reason for this correlation requires further investigation.

## Acknowledgements

This study was supported by the Affiliated Provincial Hospital of Anhui Medical University.

## Conflict of Interest

The Authors declare that they have no conflict of interests.

## References

- 1) YUCESOY G, OZKAN S, BODUR H, TAN T, CALI KAN E, VURAL B, CORAKCI A. Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. *Arch Gynecol Obstet* 2005; 273: 43-49.
- 2) AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol* 2013; 122: 1122-1131.
- 3) REDMAN CW, SARGENT IL. Latest advances in understanding preeclampsia. *Science* 2005; 308: 1592-1594.
- 4) HUPPERTZ B. Placental origins of preeclampsia: challenging the current hypothesis. *Hypertension* 2008; 51: 970-975.
- 5) YAN YH, YI P, ZHENG YR, YU LL, HAN J, HAN XM, LI L. Screening for preeclampsia pathogenesis related genes. *Eur Rev Med Pharmacol Sci* 2013; 17: 3083-3094.
- 6) GAMMILL HS, ROBERTS JM. Emerging concepts in preeclampsia investigation. *Front Biosci* 2007; 12: 2403-2411.
- 7) SARGENT IL, BORZYCHOWSKI AM, REDMAN CW. Immunoregulation in normal pregnancy and preeclampsia: an overview. *Reprod Biomed Online* 2007; 14: 111-117.
- 8) ROBERTS JM, HUBEL CA. The two stage model of preeclampsia: variations on the theme. *Placenta* 2009; 30: S32-37.
- 9) PALEI AC, SPRADLEY FT, WARRINGTON JP, GEORGE EM, GRANGER JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. *Acta Physiologica* 2013; 208: 224-233.
- 10) LEIBERMAN JR, FRASER D, KASIS A, MAZOR M. Reduced frequency of hypertensive disorders in placenta previa. *Obstet Gynecol* 1991; 77: 83-86.
- 11) BIENIARZ J. The patho-mechanism of late pregnancy toxemia and obstetrical hemorrhages. II. Placental site and venous drainage of the pregnant uterus. *Am J Obstet Gynecol* 1959; 78: 385-398.
- 12) NICOLAIDES KH, FARATIAN B, SYMONDS EM. Effect on low implantation of the placenta on maternal blood pressure and placental function. *BJOG* 1982; 89: 806-810.
- 13) ANANTH CV, BOWES WA, JR., SAVITZ DA, LUTHER ER. Relationship between pregnancy-induced hypertension and placenta previa: a population-based study. *Am J Obstet Gynecol* 1997; 177: 997-1002.
- 14) WANG JC, HIN LY, NG KB. Pregnancy-induced hypertension and placenta previa: a racial and geographical perspective. *Int J Gynaecol Obstet* 1999; 67: 177-178.
- 15) HUNG TH, HSIEH CC, HSU JJ, CHIU TH, LO LM, HSIEH TT. Risk factors for placenta previa in an Asian population. *Int J Gynaecol Obstet* 2007; 97: 26-30.
- 16) ROSENBERG T, PARIENTE G, SERGIENKO R, WIZNITZER A, SHEINER E. Critical analysis of risk factors and outcome of placenta previa. *Arch Gynecol Obstet* 2011; 284: 47-51.
- 17) HASEGAWA J, SEKIZAWA A, FARINA A, NAKAMURA M, MATSUOKA R, ICHIZUKA K, OKAI T. Location of the placenta or the umbilical cord insertion site in the lowest uterine segment is associated with low maternal blood pressure. *BJOG* 2011; 118: 1464-1469.
- 18) ADAM I, HAGGAZ AD, MIRGHANI OA, ELHASSAN EM. Placenta previa and pre-eclampsia: analyses of 1645 cases at medani maternity hospital, Sudan. *Front Physiol* 2013; 4: 32.
- 19) RAO KP, BELOGOLOVKIN V, YANKOWITZ J, SPINNATO JA, 2ND. Abnormal placentation: evidence-based diagnosis and management of placenta previa, placenta accreta, and vasa previa. *Obstet Gynecol Surv* 2012; 67: 503-519.
- 20) HIGGINS JP, THOMPSON SG, DEEKS JJ, ALTMAN DG. Measuring inconsistency in meta-analyses. *Br Med J* 2003; 327: 557-560.
- 21) DERSIMONIAN R, LAIRD N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177-188.
- 22) THORNTON A, LEE P. Publication bias in meta-analysis: its causes and consequences. *J Clin Epidemiol* 2000; 53: 207-216.
- 23) EGGER M, DAVEY SMITH G, SCHNEIDER M, MINDER C. Bias in meta-analysis detected by a simple, graphical test. *Br Med J* 1997; 315: 629-634.
- 24) JELSEMA RD, BHATIA RK, ZADOR IE, BOTTOMS SF, SOKOL RJ. Is placenta previa a determinant of preeclampsia? *J Perinat Med* 1991; 19: 485-488.
- 25) LEIBERMAN JR, FRASER D, KASIS A, MAZOR M. Reduced frequency of hypertensive disorders in placenta previa. *Obstet Gynecol* 1991; 77: 83-86.
- 26) COBO E, CANAVAL H, FONSECA J. Severe preeclampsia and postpartum eclampsia associated with placenta previa and cesarean and hysterectomy: a case report. *Am J Perinatol* 1994;

- 11: 288-289.
- 27) WATANABE K, KIMURA C, IWASAKI A, MORI T, MATSUSHITA H, SHINOHARA K, WAKATSUKI A, GOSHO M, MIYANO I. Pregnancy-induced hypertension is associated with an increase in the prevalence of cardiovascular disease risk factors in Japanese women. *Menopause* 2015; 22: 656-659.
- 28) VEERBEEK JH, HERMES W, BREIMER AY, VAN RIJN BB, KOENEN SV, MOL BW, FRANX A, DE GROOT CJ, KOSTER MP. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. *Hypertension* 2015; 65: 600-606.
- 29) DUCKITT K, HARRINGTON D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *Br Med J* 2005; 330: 565-567.
- 30) MORTENSEN JT, THULSTRUP AM, LARSEN H, MOLLER M, SORENSEN HT. Smoking, sex of the offspring, and risk of placental abruption, placenta previa, and preeclampsia: a population-based cohort study. *Acta Obstet Gynecol Scand* 2001; 80: 894-898.
- 31) BIENIARZ J. The patho-mechanism of late pregnancy toxemia and obstetrical hemorrhages. I. Contradiction in the clinical pictures of eclampsia and placenta previa depending upon the placental site. *Am J Obstet Gynecol* 1958; 75: 444-453.
- 32) BROSENS IA. Morphological changes in the utero-placental bed in pregnancy hypertension. *Clin Obstet Gynaecol* 1977; 4: 573-593.
- 33) BRENNER WE, EDELMAN DA, HENDRICKS CH. Characteristics of patients with placenta previa and results of "expectant management." *Am J Obstet Gynecol* 1978; 132: 180-191.
- 34) NEWTON ER, BARSS V, CETRULO CL. The epidemiology and clinical history of asymptomatic midtrimester placenta previa. *Am J Obstet Gynecol* 1984; 148: 743-748.